If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D in children aged one and older diagnosed with stage 2 T1D Tzield slows disease progression by ...

Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 ...

If approved, Tzield would become the first disease-modifying therapy to delay stage three type-1 diabetes for children aged one and older who currently have stage two of the disease. The FDA’s review ...

Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalled Tzield pushed back after adverse event reports; bitopertin delayed two weeks amid efficacy and ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv) to expand the current age indication from ...

Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 diabetes (T1D), in children as young as one. The FDA started a priority ...

Sanofi ( (SNY)) has shared an announcement. On January 5, 2026, Sanofi announced that the US Food and Drug Administration has accepted for priority review a supplemental biologics license application ...

Sanofi SNY announced that the FDA has accepted a regulatory filing seeking to expand the use of its type 1 diabetes (T1D) drug, Tzield (teplizumab), in individuals aged one year and older. The agency ...